The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2017 | What is the rationale for novel combination therapies?
Niels van de Donk, MD, PhD, from the University Medical Center Utrecht, Utrecht, the Netherlands, discusses the rationale behind novel combination therapies at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. He highlights important factors including the mechanism of action and resistance as well as toxicity of the single agents, and whether these are additive in combination treatments. Dr van de Donk also mentions the challenges associated with using laboratory based research to determine drug effects in patients. He describes the research which led to the Phase III POLLUX study (NCT02076009), and points out that pre-clinical testing can lead to the development of effective combinations which are well tolerated.
